Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc (RBOT) combines advanced robotics with virtual reality to transform minimally invasive surgery. This news hub provides investors and healthcare professionals with essential updates about the company's technological advancements and market position.
Access real-time information about surgical robotics innovations, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, product development announcements, and clinical trial updates directly impacting the future of abdominal surgery techniques.
Key focus areas include 3D visualization systems, single-port surgical interfaces, and integration with existing hospital workflows. Stay informed about developments in robotic-assisted procedures that enhance surgical precision while reducing patient recovery times.
Bookmark this page for verified updates about RBOT's progress in medical robotics. Regularly updated content ensures you maintain current awareness of technological breakthroughs and industry partnerships shaping modern surgical practices.
Vicarious Surgical Inc. (NYSE: RBOT), a next-generation robotics technology company, reported its Q2 2024 financial results. The company is on track to achieve its V1.0 integration milestone this fall and aims for its first clinical patient around this time next year. Key highlights include:
- Partnership agreement with LSU Health New Orleans, the fifth U.S. hospital system to partner with Vicarious Surgical
- Operating expenses decreased by 17% to $17.7 million
- Adjusted net loss of $16.8 million ($2.86 per share)
- GAAP net loss of $15.2 million ($2.59 per share)
- Cash and investments of $73.2 million as of June 30, 2024
- Q2 2024 cash burn rate of $10.9 million
- Full year 2024 cash burn guidance reiterated at approximately $50 million
Vicarious Surgical (NYSE: RBOT) has signed a strategic development agreement with LSU Health New Orleans, Louisiana's flagship academic health sciences center. This partnership will provide Vicarious Surgical access to LSU Health's network of experienced robotic surgeons and supporting staff. The collaboration aims to validate training protocols and identify drivers of surgeon adoption for Vicarious Surgical's V1.0 system.
LSU Health New Orleans, which partners with University Medical Center (UMC), treats over 200,000 patients annually and is responsible for more than 1 million patient visits across its broader system. The partnership will allow Vicarious Surgical to conduct formative studies on the clinical and economic value of their system, particularly in regional care settings with an academic focus.
Vicarious Surgical Inc. (NYSE: RBOT), a next-generation robotics technology company focused on improving surgical robotics, has announced its plans to report second quarter 2024 financial results on August 12, 2024, after the market closes. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Investors can participate in the call by dialing +1 833-470-1428 (domestic) or +1 404-975-4839 (international) using the access code 997268. Additionally, a live and archived webcast of the event will be available on the company's investor relations website.
Vicarious Surgical (NYSE: RBOT, RBOT WS) announced a 1-for-30 reverse stock split for its Class A and Class B common stock, effective June 12, 2024. This move aims to raise the company's share price to meet NYSE listing requirements. Post-split, Class A common stock will reduce from approximately 156.76 million to about 5.23 million shares, and Class B from 19.62 million to roughly 654,000 shares. Trading on a post-split basis begins on June 13, 2024, under the symbol 'RBOT'. The split will uniformly affect all stockholders without changing ownership percentages, except for fractional shares, which will be paid in cash. Warrants will also be adjusted, with the exercise price changing to $345 per share.
Vicarious Surgical Inc. (RBOT) reported its first-quarter 2024 financial results, showcasing a decrease in operating expenses, R&D expenses, general and administrative expenses, and sales and marketing expenses compared to the previous year. The company reported an adjusted net loss of $15.1 million, equating to a loss of $0.09 per share, and a GAAP net loss of $17.0 million, or a net loss per share of $0.10 for the same period. Vicarious Surgical had $84.1 million in cash and investments as of March 31, 2024, with a cash burn rate of $14.1 million for the first quarter. The company reiterated its expected full-year 2024 cash burn of approximately $50 million.
